

ORIGINAL ARTICLE

# Association of vitamin D receptor gene *fok1* polymorphism with bone health in Pakistani population

Najam Farooq<sup>1</sup>, Anwar Ullah<sup>2</sup>, Abida Arshad<sup>3</sup>, Navida Riaz<sup>1</sup>, Jabar Zaman Khan<sup>1</sup>, Sobia Tabassum<sup>1</sup>, Muhammad Arshad Malik<sup>1\*</sup>

## ABSTRACT

**Background:** Osteoporosis is the bone disease characterized by demineralization of the bone. One of the most important genetic factors responsible for the osteoporosis is the vitamin D receptor (VDR) gene polymorphism. A translocation polymorphism which changes the codon from ATG to ACG has been associated with bone mineral density (BMD) variation and severity of the disease in patients of osteoporosis. The objective of the study was to find association of VDR *Fok1* polymorphism with bone mineral density

**Methods:** This case control study was design to find the association of the VDR *Fok1* polymorphism with bone health in Pakistani osteoporotic patients. The study was conducted at Islamabad Diagnostic center from 2014 to July 2016. Total of 156 participant (osteoporotic patients  $n = 78$  and normal health controls  $n = 78$  case control) were enrolled in the study. Polymerase chain Reaction restriction length polymorphism (PCR-RFLP) was used to genotype VDR *Fok1* polymorphism. Bidirectional sanger sequencing was used to verify the PCR-RFLP results with randomly picked  $n = 10$  samples from both controls and patients. Commercial kits were used to estimate serum calcium and vitamin D level while dual-energy X-ray absorptiometry scan was used to measure the bone mineral density. The data were analyzed statistically using Statistical package for the social sciences (SPSS).

**Result:** F-allele increased the risk for decrease bone mineral density and osteopenia nearly threefold [Odds Ratio (OR): 2.8; 95% Confidence Interval (CI): 3.2-19.0;  $p \leq 0.001$ ]. The genotype frequencies (Ff+ff vs. FF) showed an increase risk of disease (OR=6.79; 95% CI=3.41-22.6;  $p < 0.001$ ). The OR cannot be calculated for recessive model since there was no ff genotype in the control group. Serum vitamin D and calcium was significantly lower in patients with mutant polymorph and their BMD was also significantly lower as compared to controls

**Conclusion:** VDR *Fok1* polymorphism is significantly associated with low mineral bone density, serum calcium and serum vitamin D level in Pakistani cohort.

**Keywords:** VDR, *Fok1*, BMD, osteoporosis.

## Introduction

Vitamin D is an imperative factor that is either of dietary sources or synthesized in the skin during sunlight. Vitamin D is essential for many biological functions, but the most important among these are bone health. It acts by binding to the vitamin D receptor (VDR) for downstream process. By binding to VDR it mediates, it modulates the transcription of gene which is involved in calcium binding protein osteocalcin [1-3]. The VDR gene consists of 11 exons and 75 kb long which occupy the q arm of chromosome 12 [4-6]. VDR is the main role player of the bone health and mass. It harbors many polymorphisms which are associated with increased risk of bone diseases. These polymorphisms increase

the risk of bone disease because they cannot bind and process vitamin D as required. These polymorphs are

**Correspondence to:** Muhammad Arshad Malik

\*Department of Biological Sciences, International Islamic University Islamabad, Pakistan.

**Email:** m.arshad@iiu.edu.pk

Full list of author information is available at the end of the article.

**Received:** 04 May 2020 | **Accepted:** 03 July 2020

\*Najam Farooq and Anwar Ullah contributed equally to this paper.



named after the restriction enzymes which are used in its identification by Polymerase Chain Reaction- Restriction Fragment Length Polymorphism (PCR-RFLP). The widely studied polymorphs are *ApaI*, *BsmI*, *FokI*, and *TaqI* [7-10]. Many studies have also been conducted to establish an association of polymorphism with bone mineral density in elderly patients [11,12]. The *FokI* polymorphism is a T/C transition polymorphism (ATG to ACG) at the first of two potential translation initiation sites in exon II [13] which has been identified using the *FokI* restriction endonuclease [14].

Although the potential risk of bone and other disease are associated with VDR polymorphism [15]. But these risks can be modulated by race, ethnicity, and diet habit [16]. The function of most of the polymorphism associated with risk has yet to be elucidated. Thus, the association of the polymorphism does not necessarily be the cause of disease for all the population [12]. Numerous studies have been published on the role of VDR and bone health but there is no study if the polymorphs in Pakistani population could affect the bone health; hence, the present study was designed to find the possible association and risk of bone diseases in Pakistani population with bone disease and to compare with control group. A case control study was carried out to study *FokI* polymorphism with osteoporosis osteopenia and bone mineral density in Pakistani population.

## Methods

### *Patients' recruitment and data collection*

Osteoporotic patients visited the private clinic of Islamabad diagnostic center (IDC) during July 2013 till July 2014 was enrolled in the study. This study was approved by Institutional ethics committee of International Islamic University, Islamabad, Pakistan, and IDC and was in concordance to Helsinki Declaration. The patients were diagnosed clinically and dual-energy X-ray absorptiometry (DEXA) scan was performed to measure bone mineral density and stage the disease. Age, gender, and ethnic matched controls were also included in the study. Blood were collected in two different tubes, i.e., Ethylenediaminetetraacetic acid (EDTA) tubes for DNA extraction and plain tubes for serum extraction.

The genomic DNA was extracted using commercial DNA extraction kit DNeasy Blood & Tissue Kit [17]. Serum was obtained by centrifugation of the clotted blood at 6,000 rpm for 10 minutes. The serum was separated in clean tubes. Both serum and DNA were stored at  $-20^{\circ}\text{C}$  for further analysis.

### *Genotyping*

Genotyping of VDR *FokI* polymorphism was performed as describe previously [18]. Briefly, a PCR was performed with a total volume of 20  $\mu\text{l}$ . The composition of the PCR reaction was as 2  $\mu\text{l}$  of  $10\times$  Taq Buffer, 1  $\mu\text{l}$  of 20 mM  $\text{MgCl}_2$ , 2  $\mu\text{l}$  10 mM dNTPs 1  $\mu\text{l}$  of 10 pmol of each primer, 0.2  $\mu\text{l}$  of 5 U/ $\mu\text{l}$  Taq polymerase and 12.8  $\mu\text{l}$  PCR grade water for each

reaction. PCR product 265 bp was obtained using Forward 5'- AGCTGGCCCTGGCACTGACTCTGCTCT -3' and Reverse 5'- ATGGAACACCTTGCTTCTTCTCCCTC -3'.

Initial denaturation of  $94^{\circ}\text{C}$  for 2 minutes  $1\times$ , followed by  $94^{\circ}\text{C}$  for 30 seconds  $58^{\circ}\text{C}$  for 45 seconds, and annealing at  $72^{\circ}\text{C}$  for 45 seconds  $30\times$ , and final extension at  $72^{\circ}\text{C}$  for 10 minutes were done. The PCR product obtained were subjected to digestion by *FokI* endonuclease enzyme in 20  $\mu\text{l}$  of reaction volume, i.e., 12.5  $\mu\text{l}$  of PCR product, 1.5  $\mu\text{l}$  of *FokI* endonuclease enzyme, and 6  $\mu\text{l}$  of 1X buffer. The reaction mixture was incubated at  $37^{\circ}\text{C}$  for 4 hours and then subjected to 2% agarose gel electrophoresis. The digested product split in to two distinct 296 bp and 69 bp fragments figure. Genotypes were assigned after visualizing in UV transilluminator on the basis of the size of fragments.

### *Estimation of serum vitamin D and calcium*

The level of serum vitamin D was measured by commercially available diagnostic kit by Immundiagnostik AG, Germany. Principal of competitive Enzyme Linked Immunosorbant Assay (ELISA) is used which allows accurate quantitative determination of the serum vitamin. Vitamin D is considered as low when it is below 30 ng/ml and toxic when its level is  $>100$  ng/ml.

Serum calcium was measured by using commercially available calcium assay on the ARCHITECT Systems <sup>TM</sup> (Abbott, USA) according to the manufacturer instruction. The results were interpreted as kit instruction provided.

### *DEXA scan imaging*

DEXA scan imaging was done to find the bone mineral density. Dual-energy X-ray absorptiometry (DEXA) scan (Hologic, Waltham, MA) was used measure Bone Mineral Density (BMD) at hip and lumbar spine region. The reference value of T and Z scores was entered in the DEXA machine with software for the Asian reference value. We considered osteopenia when the T score of total lumbar spine or total hip was between  $-1$  and  $-2.5$ , and osteoporosis was considered when the T score was  $<-2.5$  [19].

## Results

Seventy eight diagnosed patients were enrolled in the study where the male and female numbers were 25 (32%) and 53(67%), respectively. The mean age for the male was 45.04 years and the females were around 52.45 years. Seventy eight healthy controls were also enrolled in the study in whom 37 (47.4%) were male and 41 (52.56%) were females.

### *Serum calcium and vitamin D level*

Calcium is important for many body functions. The normal range of free calcium is 8.4-10.4 mg/dl. Serum calcium was measured for all the patients and control group. The hypocalcemia for the patients were  $n = 29$

(17.17%) in which male were  $n = 8$  (10.15%) and female were  $n = 21$  (26.92%), while the remaining patients were normal for serum calcium level. No controls were found to be hypocalcemic.

Vitamin D is mainly involved in the bone health therefore serum vitamin D was measured for all the patients and control group. The hypovitaminosis D for the patients were  $n = 50$  (61.10%) in which male were  $n = 31$  (39.74%) and female were  $n = 19$  (24.35%), while the remaining patients were normal for serum vitamin D level. The hypervitaminosis D for the patients were  $n = 3$  (3.84%) in which male was  $n = 1$  (1.74%) and female were  $n = 2$  (2.56%), while the remaining patients were normal for serum vitamin D level.

### Bone mineral density

The bone mineral densities were measured for all the patients and control using DEXA scan. The osteopenia for the patients were  $n = 41$  (52.56%) in which male was  $n = 16$  (20.51%) and female were  $n = 25$  (32.05%). The osteoporosis for the patients were  $n = 19$  (24.35%) in which male was  $n = 4$  (5.21%) and female were  $n = 15$  (19.23%), while the remaining patients were normal for bone mineral density. All the control individuals were normal for bone mineral density.

### Goodness-of-fit test for Hardy-Weinberg equilibrium and comparison of FokI polymorphs between cases and controls

There was no deviation from the Hardy-Weinberg genetic equilibrium for the genotypic distribution of

VDR Polymorph in group as shown in Table 1. In the analyzed VDR polymorph, Wild (FF) genotype was with highest frequency, the Ff heterozygous was found to be modest frequency, and the Mutant (ff) genotype was with lowest frequency. The wild genotype for the disease group were  $n = 45$  (57.69%) and control were  $n = 72$  (92.30%). The heterozygous genotype for disease group were  $n = 29$  (37.69%) and control were  $n = 6$  (7.69%). The homozygous mutant genotype disease group were  $n = 4$  (5.12%), and no control was found for homozygous mutant as shown in table.

### Association analysis


The F-allele which is minor allele and increase the risk of functionally deficient form of vitamin D receptor increased the risk for decrease bone mineral density and osteopenia nearly threefold [Odds Ratio (OR): 2.8; 95% Confidence Interval (CI): 3.2-19.0;  $p \leq 0.001$ ]. The genotype frequencies (Ff+ff vs. FF) were also compared under dominant model and they even showed an increase risk of disease (OR=6.79; 95% CI=3.41-22.6;  $p \leq 0.001$ ). The OR cannot be calculated for recessive model since there was no ff genotype in the control group. In case of recessive model (ff vs. FF + Ff), OR for ff is indefinitely large.

### Discussion

Bone is the structural framework of the body and is metabolically active to support the weight of the body. Osteocytes, osteoclasts, and osteoblast are continuously active to maintain the bone health to be strong enough

**Table 1.** Genotypic, allelic distribution, and risk assessment.

	Genotype distribution			Total	HWE (p-value)
	FF	Ff	ff		
Disease group	45 (57.69%)	29 (53.69%)	4 (5.12%)	78	0.80
Control	72(92.7%)	6 (7.69%)	0 (0%)	78	0.72
Total	117	35	4	156	0.48
	Allelic distribution		Total		
	F	f			
Disease group	119 (76.28%)	37 (23.71%)	156		
Control	150 (96.15%)	6 (3.84%)	156		
Total	269	43	312		
Genetic model and statistical data					P
Genetic model	Odds ratio (95% CI)	Chi-square	Degrees of freedom		
Allele contrast (F vs. f)	2.8 (3.2-19.0)	25.92	1		<0.001
Dominant (Ff+ff vs. FF)	6.79 (3.41-22.6)	24.92	1		<0.001
Recessive (ffvs FF+Ff)	Infinite*	Infinity	1		0.12



**Figure 1.** Restriction Endonuclease digestion for *FokI* polymorphism. M is DNA ladder Lan 1, 2 and 3 indicate ff genotype consisting of 196 and 67 bp fragments, lane 4, 5 and 6 shows Ff genotype consisting of 265 and 196 bp fragments, while lane 7 and 8 indicated undigested product of 265 bp is the FF genotype.

to support body. These cells perform their function in close coordination to calcium, magnesium, parathyroid hormones, and vitamin D [20]. Additional factor which affect the concentration and availability of these minerals and hormones is the genetic make up of the individuals along with exposure to the environment. Hence, differential genetic makeup (polymorphs) of the vitamin D receptor affect the availability these minerals and vitamins. These polymorphs behave differentially in different population and ethnicity. Therefore, the presence of bone disorders are different in different population [21,22]. Hence, the present study was designed to find the association of *FokI* polymorphism with bone health in Pakistani population. A case control study was performed in which the wild genotype for the disease group were  $n = 45$  (57.69%) and control were  $n = 72$  (92.30%). The heterozygous genotype for disease group were  $n = 29$  (37.69%) and control were  $n = 6$  (7.69%). The homozygous mutant genotype disease group were  $n = 4$  (5.12%) and no control was found for homozygous mutant. The association studies found that the Ff, ff genotype, and frequency of the f allele is significantly associated with the low bone mineral density and the risk of osteoporosis.

The f allele which is minor allele and increase the risk of functionally deficient form of vitamin D receptor increased the risk for decrease bone mineral density and osteopenia nearly three fold (OR: 2.8; 95% CI: 3.2-19.0;  $p \leq 0.001$ ). The genotype frequencies (Ff+ff vs. FF) were also compared under dominant model and they even showed an increase risk of disease (OR=6.79; 95% CI=3.41-22.6;  $p \leq 0.001$ ).

Mohammadi et al. [23] reported a significant association between the *FokI* and *BsmI* polymorphism with osteoporosis in more than 50 reviewed studies [23]. The finding of these reported studies is consistent with our findings.

A study in Iranian population also showed similar results to our study [FF genotype  $n = 45$  (57.69%)] the FF genotype was (56.5%) and the remaining were either Ff or ff genotypes [24]. Das et al. [25] reported a very

similar results to our finding FF was 59%, Ff in 36%, and ff in 5% in Indian population, while in our study FF is 57.69%, Ff is 37.69%, and ff is 5.12% [25]. An increase heterozygous and homozygous for minor allele was reported in Italian population (FF = 33.2%, Ff = 32.8%, ff = 34%) [26]. A study in Spanish population also reported similar findings as to the Italian population FF = 40.4, Ff = 48.0, ff = 11.6% [27].

The association of lower BMD with ff genotypes is also frequently reported. Abrams et al. [28] and Hossein-Nezhad [24] reported that Ff and ff genotype increase the risk of risk of lower bone mineral density. The finding both way the genetic association of the genotype with lower BMD and frequency of the genotype in studied population is similar to our study.

## Conclusion

Genetic testing of the VDR polymorphism should be considered while treating the patients for osteoporosis and osteopenia in Pakistani population.

## Funding

None.

## Declaration of conflicting interests

The authors of this article have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.

## Ethical approval

The study was performed in accordance with the Declaration of Helsinki and was approved by the Research Ethics Committee of Islamabad Diagnostic Centre Pakistan (IDC/REC/13-1).

## Consent for publication

Written informed consent was obtained from all participants.

## Author details

Najam Farooq<sup>1</sup>, Anwar Ullah<sup>2</sup>, Abida Arshad<sup>3</sup>, Navida Riaz<sup>1</sup>, Jabar Zaman Khan<sup>1</sup>, Sobia Tabassum<sup>1</sup>, Muhammad Arshad Malik<sup>1</sup>

1. Department of Biological Sciences, International Islamic University Islamabad, Pakistan
2. Rehman Medical Institute Hayatabad Peshawar, Pakistan
3. Department of Zoology, PMAS Arid Agriculture Rawalpindi Pakistan

## References

1. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–81. <https://doi.org/10.1056/NEJMr070553>
2. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene. 2004;338(2):143–56. <https://doi.org/10.1016/j.gene.2004.05.014>
3. Walters MR. Newly identified actions of the vitamin D endocrine system. Endocr Rev. 1992;13(4):719–64. <https://doi.org/10.1210/er.13.4.719>



4. Taymans SE, Pack S, Pak E, Orban Z, Barsony J, Zhuang Z, et al. The human vitamin D receptor gene (VDR) is localized to region 12cen-q12 by fluorescent in situ hybridization and radiation hybrid mapping: genetic and physical VDR map. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*. 1999;14:1163–6. <https://doi.org/10.1359/jbmr.1999.14.7.1163>
5. Crofts LA, Hancock MS, Morrison NA, Eisman JA. Multiple promoters direct the tissue-specific expression of novel N-terminal variant human vitamin D receptor gene transcripts. *Proc Natl Acad Sci USA*. 1998;95:10529–34. <https://doi.org/10.1073/pnas.95.18.10529>
6. Miyamoto K, Kesterson RA, Yamamoto H, Taketani Y, Nishiwaki E, Tatsumi S, et al. Structural organization of the human vitamin D receptor chromosomal gene and its promoter. *Mol Endocrinol*. 1997;11:1165–79. <https://doi.org/10.1210/mend.11.8.9951>
7. Willing M, Sowers M, Aron D, Clark MK, Burns T, Bunten C, et al. Bone mineral density and its change in white women: estrogen and vitamin D receptor genotypes and their interaction. *J Bone Miner Res*. 1998;13(4):695–705. <https://doi.org/10.1359/jbmr.1998.13.4.695>
8. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, et al. Prediction of bone density from vitamin D receptor alleles. *Nature*. 1994;367(6460):284–7. <https://doi.org/10.1038/367284a0>
9. Sainz J, Van Tornout JM, Loro ML, Sayre J, Roe TF, Gilsanz V. Vitamin D-receptor gene polymorphisms and bone density in prepubertal American girls of Mexican descent. *N Engl J Med*. 1997;337(2):77–82. <https://doi.org/10.1056/NEJM199707103370202>
10. Gennari L, Becherini L, Masi L, Mansani R, Gonnelli S, Cepollaro C, et al. Vitamin D and estrogen receptor allelic variants in Italian postmenopausal women: evidence of multiple gene contribution to bone mineral density. *J Clin Endocrinol Metab*. 1998;83(3):939–44. <https://doi.org/10.1210/jcem.83.3.4649>
11. Ferrari S, Rizzoli R, Chevalley T, Slosman D, Eisman JA, Bonjour JP. Vitamin-D-receptor-gene polymorphisms and change in lumbar-spine bone mineral density. *Lancet*. 1995;345(8947):423–4. [https://doi.org/10.1016/S0140-6736\(95\)90404-2](https://doi.org/10.1016/S0140-6736(95)90404-2)
12. Morita A, Iki M, Dohi Y, Ikeda Y, Kagamimori S, Kagawa Y, et al.; JPOS Study Group. Prediction of bone mineral density from vitamin D receptor polymorphisms is uncertain in representative samples of Japanese Women. The Japanese Population-based Osteoporosis (JPOS) Study. *Int J Epidemiol*. 2004;33(5):979–88. <https://doi.org/10.1093/ije/dyh245>
13. Baker AR, McDonnell DP, Hughes M, Crisp TM, Mangelsdorf DJ, Haussler MR, et al. Cloning and expression of full-length cDNA encoding human vitamin D receptor. *Proc Natl Acad Sci USA*. 1988;85:3294–8. <https://doi.org/10.1073/pnas.85.10.3294>
14. Gross C, Eccleshall TR, Malloy PJ, Villa ML, Marcus R, Feldman D. The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-American women. *J Bone Miner Res*. 1996;11:1850–5. <https://doi.org/10.1002/jbmr.5650111204>
15. Zmuda JM, Cauley JA, Ferrell RE. Molecular epidemiology of vitamin D receptor gene variants [Internet]. *Epidemiol Rev*. 2000;22(2):203–17. <https://doi.org/10.1093/oxfordjournals.epirev.a018033>
16. Valdivielso JM, Fernandez E. Vitamin D receptor polymorphisms and diseases. *Clin Chim Acta*. 2006;371(1-2):1–12. <https://doi.org/10.1016/j.cca.2006.02.016>
17. Qiagen. DNeasy® Blood & Tissue Handbook For purification of total DNA from animal blood animal tissue. DNeasy® Blood & Tissue Handbook For purification of total DNA from animal blood animal tissue; 2006.
18. Harris SS, Eccleshall TR, Gross C, Dawson-Hughes B, Feldman D. The vitamin D receptor start codon polymorphism (FokI) and bone mineral density in premenopausal American black and white women. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*. 1997;12:1043–8. <https://doi.org/10.1359/jbmr.1997.12.7.1043>
19. National Osteoporosis F. America's bone health. The state of osteoporosis and low bone mass in our nation. Arlington, VA: National Osteoporosis Foundation; 2002.
20. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. *Endocr Rev*. 2000;21(2):115–37. <https://doi.org/10.1210/edrv.21.2.0395>
21. Barrett-Connor E, Siris ES, Wehren LE, Miller PD, Abbott TA, Berger ML, et al. Osteoporosis and fracture risk in women of different ethnic groups. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*. 2005;20: 185–94. <https://doi.org/10.1359/JBMR.041007>
22. Looker AC, Orwoll ES, Johnston CC JR, Lindsay RL, Wahner HW, Dunn WL, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. *J Bone Miner Res*. 1997;12(11):1761–8. <https://doi.org/10.1359/jbmr.1997.12.11.1761>
23. Mohammadi Z, Fayyazbakhsh F, Ebrahimi M, Amoli MM, Khashayar P, Dini M, et al. Association between vitamin D receptor gene polymorphisms (FokI and BsmI) and osteoporosis: a systematic review. *J Diabetes Metab Disord*. 2014;13(1):98. <https://doi.org/10.1186/s40200-014-0098-x>
24. Hossein-Nezhad A. Evaluating of VDR gene variation and its interaction with Immune Regulatory Molecules in Osteoporosis. *Iranian Journal of Public*. 2009;38.
25. Bhanushali AA, Lajpal N, Kulkarni SS, Chavan SS, Bagadi SS, Das BR. Frequency of fokI and taqI polymorphism of vitamin D receptor gene in Indian population and its association with 25-hydroxyvitamin D levels. *Indian J Hum Genet*. 2009;15(3):108–13. <https://doi.org/10.4103/0971-6866.60186>
26. Falchetti A, Sferrazza C, Cepollaro C, Gozzini A, Del Monte F, Masi L, et al. FokI polymorphism of the vitamin D receptor gene correlates with parameters of bone mass and turnover in a female population of the Italian island of Lampedusa. *Calcif Tissue Int*. 2007;80(1):15–20. <https://doi.org/10.1007/s00223-005-0295-1>

27. Quesada JM, Casado A, Díaz C, Barrios L, Cuenca-Acevedo R, Dorado G. Allele-frequency determination of BsmI and FokI polymorphisms of the VDR gene by quantitative real-time PCR (QRT-PCR) in pooled genomic DNA samples. *J Steroid Biochem Mol Biol.* 2004;89-90(1-5):209-214 <https://doi.org/10.1016/j.jsbmb.2004.03.085>
28. Abrams SA, Griffin IJ, Hawthorne KM, Chen Z, Gunn SK, Wilde M, et al. Vitamin D receptor FokI polymorphisms affect calcium absorption, kinetics, and bone mineralization rates during puberty. *J Bone Miner Res.* 2005;20(6):945–53. <https://doi.org/10.1359/JBMR.050114>